Karine Miquel‐Hébert

2.4k citations

20 papers · 1.7k indexed · 1 hit paper · h-index 16

Surgery top 2%
Cardiology and Cardiovascular Medicine top 2%
Pulmonary and Respiratory Medicine top 5%
Radiology, Nuclear Medicine and Imaging top 5%
Biomedical Engineering

Co-authors: Patrick W. Serruys Yoshinobu Onuma Leif Thuesen Susan Veldhof Cécile Dorange Dariusz Dudek Héctor M. García‐García John A. Ormiston
Topics: Coronary Interventions and Diagnostics (20 papers)Cardiac Imaging and Diagnostics (13 papers)Cardiac Valve Diseases and Treatments (8 papers)
Cited by: Cardiology and Cardiovascular Medicine Surgery Pulmonary and Respiratory Medicine
Journals: The Lancet Circulation Journal of the American College of Cardiology
Partner nations: Netherlands New Zealand France

In The Last Decade

Karine Miquel‐Hébert

20 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods

2009 584 citations Patrick W. Serruys, John A. Ormiston et al. The Lancet profile →

Peers

Countries citing papers authored by Karine Miquel‐Hébert

Since Specialization

Citations

This map shows the geographic impact of Karine Miquel‐Hébert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karine Miquel‐Hébert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karine Miquel‐Hébert more than expected).

Fields of papers citing papers by Karine Miquel‐Hébert

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karine Miquel‐Hébert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karine Miquel‐Hébert. The network helps show where Karine Miquel‐Hébert may publish in the future.

Co-authorship network of co-authors of Karine Miquel‐Hébert

This figure shows the co-authorship network connecting the top 25 collaborators of Karine Miquel‐Hébert. A scholar is included among the top collaborators of Karine Miquel‐Hébert based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karine Miquel‐Hébert. Karine Miquel‐Hébert is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Five-year long-term clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery disease: the SPIRIT II trial 2013 ·EuroIntervention ·Yoshinobu Onuma,Karine Miquel‐Hébert,Patrick W. Serruys	42
2	Four-year clinical follow-up of the ABSORB everolimus-eluting bioresorbable vascular scaffold in patients with de novo coronary artery disease: the ABSORB trial 2012 ·EuroIntervention ·Dariusz Dudek,Yoshinobu Onuma,John Ormiston,Leif Thuesen,Karine Miquel‐Hébert,Patrick W. Serruys	101
3	ABSORB II randomized controlled trial 2012 ·American Heart Journal ·Roberto Diletti,Patrick W. Serruys,Vasim Farooq,Krishnankutty Sudhir,Cécile Dorange,Karine Miquel‐Hébert,Susan Veldhof,Richard Rapoza,Yoshinobu Onuma,Héctor M. García‐García,Bernard Chevalier	92
4	VASCULAR RESPONSE OF THE SEGMENTS ADJACENT TO THE PROXIMAL AND DISTAL EDGES OF THE ABSORB EVEROLIMUS-ELUTING BIORESORBABLE VASCULAR SCAFFOLD: 6 MONTHS AND 1 YEAR FOLLOW-UP ASSESSMENT. A SERIAL INTRAVASCULAR ULTRASOUND RADIOFREQUENCY DATA ANALYSIS FROM THE FIRST IN MAN ABSORB COHORT B TRIAL 2012 ·Journal of the American College of Cardiology ·Bill D. Gogas,Patrick W. Serruys,Vasim Farooq,Salvatore Brugaletta,Maria Radu,Jung Ho Heo,Robert‐Jan van Geuns,Evelyn Regar,Bernard De Bruyne,Bernard Chevalier,Leif Thuesen,Jacques Koolen,Stefan Windecker,Karine Miquel‐Hébert,Cécile Dorange,Richard Rapoza,(unknown)	1
5	Circumferential evaluation of the neointima by optical coherence tomography after ABSORB bioresorbable vascular scaffold implantation: Can the scaffold cap the plaque? 2011 ·Atherosclerosis ·Salvatore Brugaletta,Maria Radu,Héctor M. García‐García,Jung Ho Heo,Vasim Farooq,Chrysafios Girasis,Robert‐Jan van Geuns,Leif Thuesen,Dougal McClean,Bernard Chevalier,Stephan Windecker,Jacques Koolen,Richard Rapoza,Karine Miquel‐Hébert,John A. Ormiston,Patrick W. Serruys	96
6	Monitoring In Vivo Absorption of a Drug-Eluting Bioabsorbable Stent With Intravascular Ultrasound-Derived Parameters 2010 ·JACC: Cardiovascular Interventions ·Nico Bruining,Sebastiaan de Winter,Jos R.T.C. Roelandt,Evelyn Regar,Iddo Heller,Ron T. van Domburg,Ronald Hamers,Yoshinobu Onuma,Darius Dudek,Mark Webster,Leif Thuesen,John A. Ormiston,Wai‐Fung Cheong,Karine Miquel‐Hébert,Susan Veldhof,Patrick W. Serruys	30
7	Clinical Follow-Up 3 Years After Everolimus- and Paclitaxel-Eluting Stents 2010 ·JACC: Cardiovascular Interventions ·Adriano Caixeta,Alexandra J. Lansky,Patrick W. Serruys,James Hermiller,Peter Ruygrok,Yoshinobu Onuma,Paul Gordon,Manejeh Yaqub,Karine Miquel‐Hébert,Susan Veldhof,Poornima Sood,Xiaolu Su,(unknown),Krishnankutty Sudhir,Gregg W. Stone	37
8	Four‐year clinical follow‐up of the XIENCE V everolimus‐eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: The SPIRIT II trial 2010 ·Catheterization and Cardiovascular Interventions ·Scot Garg,Patrick W. Serruys,Karine Miquel‐Hébert,(unknown)	21
9	A pooled gender based analysis comparing the XIENCE V® everolimus-eluting stent and the TAXUS paclitaxel-eluting stent in male and female patients with coronary artery disease, results of the SPIRIT II and SPIRIT III studies: two-year analysis 2010 ·EuroIntervention ·Ashok Seth,Patrick W. Serruys,Alexandra J. Lansky,James Hermiller,Yoshinobu Onuma,Karine Miquel‐Hébert,Shui Yu,Susan Veldhof,Poornima Sood,Krishnankutty Sudhir,Gregg W. Stone	22
10	Five‐year long‐term clinical follow‐up of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: The SPIRIT FIRST trial 2010 ·Catheterization and Cardiovascular Interventions ·Marcus Wiemer,Patrick W. Serruys,Karine Miquel‐Hébert,Franz‐Josef Neumann,Jan J. Piek,Eberhard Grube,Jürgen Haase,Leif Thuesen,Christian W. Hamm	56
11	Efficacy of everolimus eluting stent implantation in patients with calcified coronary culprit lesions: Two‐year angiographic and three‐year clinical results from the SPIRIT II study 2010 ·Catheterization and Cardiovascular Interventions ·Yoshinobu Onuma,Shuzou Tanimoto,Peter Ruygrok,Jörg Neuzner,Jan J. Piek,Ashok Seth,Joachim Schofer,Gert Richardt,Marcus Wiemer,Didier Carrié,Leif Thuesen,Cécile Dorange,Karine Miquel‐Hébert,Susan Veldhof,Patrick W. Serruys	100
12	An everolimus‐eluting stent versus a paclitaxel‐eluting stent in small vessel coronary artery disease: A pooled analysis from the SPIRIT II and SPIRIT III trials 2010 ·Catheterization and Cardiovascular Interventions ·Antonio L. Bartorelli,Patrick W. Serruys,Karine Miquel‐Hébert,Shui Yu,(unknown),Gregg W. Stone,(unknown)	28
13	Temporal changes of coronary artery plaque located behind the struts of the everolimus eluting bioresorbable vascular scaffold 2010 ·International journal of cardiac imaging ·Salvatore Brugaletta,Héctor M. García‐García,Scot Garg,Josep Gómez‐Lara,Roberto Diletti,Yoshinobu Onuma,Robert‐Jan van Geuns,Dougal McClean,Dariusz Dudek,Leif Thuesen,Bernard Chevalier,Stephan Windecker,Robert Whitbourn,Cécile Dorange,Karine Miquel‐Hébert,Krishnankutty Sudhir,John A. Ormiston,Patrick W. Serruys	14
14	Evaluation of the Second Generation of a Bioresorbable Everolimus Drug-Eluting Vascular Scaffold for Treatment of De Novo Coronary Artery Stenosis 2010 ·Circulation ·Patrick W. Serruys,Yoshinobu Onuma,John A. Ormiston,Bernard De Bruyne,Evelyn Regar,Dariusz Dudek,Leif Thuesen,Pieter C. Smits,Bernard Chevalier,Dougal McClean,Jacques Koolen,Stephan Windecker,Robert Whitbourn,Ian T. Meredith,Cécile Dorange,Susan Veldhof,Karine Miquel‐Hébert,Richard Rapoza,Héctor M. García‐García	240
15	3-Year Clinical Follow-Up of the XIENCE V Everolimus-Eluting Coronary Stent System in the Treatment of Patients With De Novo Coronary Artery Lesions 2009 ·JACC: Cardiovascular Interventions ·Scot Garg,Patrick W. Serruys,Yoshinobu Onuma,Cécile Dorange,Susan Veldhof,Karine Miquel‐Hébert,Krishnankutty Sudhir,Jean Boland,Kurt Huber,Eulogio Garcı́a,(unknown)	78
16	A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methodsbreakdown → 2009 ·The Lancet ·Patrick W. Serruys,John A. Ormiston,Yoshinobu Onuma,Evelyn Regar,Nieves Gonzalo,Héctor M. García‐García,Koen Nieman,Nico Bruining,Cécile Dorange,Karine Miquel‐Hébert,Susan Veldhof,Mark Webster,Leif Thuesen,Dariusz Dudek	584
17	Two-Year Clinical, Angiographic, and Intravascular Ultrasound Follow-Up of the XIENCE V Everolimus-Eluting Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions 2009 ·Circulation Cardiovascular Interventions ·Bimmer E. Claessen,Marcel A.M. Beijk,Victor Legrand,Witold Rużyłło,Antonio Manari,Olivier Varenne,Maarten J. Suttorp,Jan G.P. Tijssen,Karine Miquel‐Hébert,Susan Veldhof,José P.S. Henriques,Patrick W. Serruys,Jan J. Piek	92
18	Two-Year Clinical, Angiographic, and Intravascular Ultrasound Follow-Up of the XIENCE V Everolimus-Eluting Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions: The SPIRIT II Trial 2009 ·Circulation Cardiovascular Interventions ·Bimmer E. Claessen,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),Jan G.P. Tijssen,Karine Miquel‐Hébert,(unknown),(unknown),Patrick W. Serruys,(unknown)	14
19	Differentiated analysis of an everolimus-eluting stent and a paclitaxel-eluting stent among higher risk subgroups for restenosis: results from the SPIRIT II trial 2008 ·EuroIntervention ·Ahmed A. Khattab,Gert Richardt,Vitali Verin,Henning Kelbæk,Carlos Macaya,Jacques Berland,Karine Miquel‐Hébert,Cécile Dorange,Patrick W. Serruys	11
20	Systemic exposure of everolimus after stent implantation: A pharmacokinetic study 2008 ·American Heart Journal ·Marcus Wiemer,Ashok Seth,Praveen Chandra,Jörg Neuzner,Gert Richardt,Jan J. Piek,Martin Desaga,Carlos Macaya,C.J. Bol,Karine Miquel‐Hébert,(unknown),Patrick W. Serruys	16

About Karine Miquel‐Hébert

Karine Miquel‐Hébert is a scholar working on Radiology, Nuclear Medicine and Imaging, Cardiology and Cardiovascular Medicine and Surgery, having authored 20 papers that have together received 1.7k indexed citations. Recurring topics across this work include Coronary Interventions and Diagnostics (20 papers), Cardiac Imaging and Diagnostics (13 papers) and Cardiac Valve Diseases and Treatments (8 papers). The work is most often cited by research in Cardiology and Cardiovascular Medicine (1.0k citations), Surgery (1.6k citations) and Pulmonary and Respiratory Medicine (658 citations). Karine Miquel‐Hébert has collaborated with scholars based in Netherlands, New Zealand and France. Frequent co-authors include Patrick W. Serruys, Yoshinobu Onuma, Leif Thuesen, Susan Veldhof, Cécile Dorange, Dariusz Dudek, Héctor M. García‐García, John A. Ormiston, Evelyn Regar and Nico Bruining. Their work appears in journals such as The Lancet, Circulation and Journal of the American College of Cardiology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact